Compare WGO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | OCS |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | WGO | OCS |
|---|---|---|
| Price | $43.73 | $21.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $43.00 | $39.57 |
| AVG Volume (30 Days) | ★ 709.2K | 104.2K |
| Earning Date | 12-19-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $2,875,300,000.00 | $991,999.00 |
| Revenue This Year | $3.85 | $14.53 |
| Revenue Next Year | $5.20 | $691.13 |
| P/E Ratio | $33.17 | ★ N/A |
| Revenue Growth | ★ 1.38 | N/A |
| 52 Week Low | $28.00 | $14.00 |
| 52 Week High | $50.31 | $23.08 |
| Indicator | WGO | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 64.83 |
| Support Level | $39.33 | $19.70 |
| Resistance Level | $43.38 | $22.14 |
| Average True Range (ATR) | 1.91 | 0.78 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 48.70 | 90.57 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.